



#80600 101 A
08/243279

-1-

PATENT

mk
06/24/94

2003

NONIRRITATING EMULSIONS FOR SENSITIVE TISSUE

5 The present invention generally relates to novel
pharmaceutical compositions incorporating chemicals
which are poorly soluble in water and is more particu-
larly related to a novel ophthalmic emulsion including
cyclosporin in admixture with castor oil and polysor-
bate 80 with high comfort level and low irritation
10 potential.

a
Cyclosporins ^{are} ~~is~~ a group of nonpolar cyclic
oligopeptides with known immunosuppressant activity.
In addition, as set forth in U.S. Patent No.
15 4,839,342, cyclosporin (sometimes referred to in the
literature as "cyclosporine") has been found as
effective in treating immune medicated keratoconjunc-
tivitis sicca (KCS or dry eye disease) in a patient
suffering therefrom.

20

As hereinabove noted, cyclosporin comprises a
group of cyclic oligopeptides and the major component
thereof is cyclosporin A ($C_{62}H_{111}N_{11}O_{12}$) which has been
identified along with several other minor metabolites,
25 cyclosporin B through I. In addition, a number of
synthetic analogs have been prepared.

30 In general, commercially available cyclosporins
may contain a mixture of several individual cyclo-
sporins which all share a cyclic peptide structure
consisting of eleven amino acid residues with a total
molecular weight of about 1,200, but with different
substituents or configurations of some of the amino
acids.

35

It should be appreciated that reference to the
term "cyclosporin" or "cyclosporins" is used through-

out the present specification in order to designate the cyclosporin component in the composition of the present invention.

5 However, this specific reference is intended to include any individual member of the cyclosporin group as well as admixtures of two or more individual cyclosporins, whether natural or synthetic.

10 The activity of cyclosporins, as hereinabove noted, is as an immunosuppressant and in the enhancement or restoring of lacrimal gland tearing.

15 Unfortunately, the solubility of cyclosporin in water is extremely low and as elaborated in U.S. Patent No. 5,051,402, it has been considered not merely difficult but practically impossible to prepare a pharmaceutical composition containing cyclosporin dissolved in an aqueous medium.

20 As reported, the solubility of cyclosporin in water is between about 20 $\mu\text{g/ml}$ to 30 $\mu\text{g/ml}$ for cyclosporin A. Hence, heretofore prepared formulations incorporating cyclosporin have been prepared as
25 oily solutions containing ethanol. However, these preparations limit the bioavailability to oral preparations and this is believed to be due to the separation of cyclosporin as a solid immediately after it comes into contact with water, such as in the mouth or
30 eye of a patient.

 In the case of injectable preparations of cyclosporin, they first must be diluted with physiological saline before intravenous administration but this is
35 likely to result in the precipitation of cyclosporin and therefore may be considered undesirable for intravenous administration.

Surface active agents such as polyoxyethylated castor oil have been utilized as solubilizers to inject preparations in order to prevent cyclosporin from separating. However, this also may give rise to safety problems (see U.S. Patent No. 5,051,402).

The practical usefulness of cyclosporin would be greatly enhanced if administration thereof could be effective; for example, cyclosporin's effectiveness in the treatment of ocular symptoms of Behcet's Syndrome. However, if it is administered orally for the treatment of these symptoms, the accompanying side effects due to systemic circulation may cause adverse reactions such as hypertrichosis or renal dysfunction.

On the other hand, if oily preparations containing cyclosporin are applied directly to the eyes, irritation or a clouding of visual field may result. This plus the difficulty in formulating cyclosporin limits its use in formulations that would be useful during keratoplasty as well in the treatment of herpetic keratitis and spring catarrh.

Heretofore, as for example in U.S. Patent No. 5,051,402, attempts have been made to dissolve sufficient cyclosporin in an aqueous solvent system so as to reach an effective concentration for treatment. Importantly, this solvent system does not contain any surface active agent such as polyoxyethylated castor oil.

Conceptually, the purpose of dissolving the cyclosporin in an aqueous solvent system is to enable contact with body fluids which would merely constitute dilution of the aqueous solvent system which hopefully would eliminate the immediate precipitation of cyclo-

sporin when contacted with the water content of the body fluids.

5 For direct use in the eye, cyclosporin has been formulated with a number of pharmaceutically acceptable excipients, for example, animal oil, vegetable oil, an appropriate organic or aqueous solvent, an artificial tear solution, a natural or synthetic polymer or an appropriate membrane.

10

Specific examples of these pharmaceutically acceptable excipients, which may be used solely or in combination, are olive oil, arachis oil, castor oil, mineral oil, petroleum jelly, dimethyl sulfoxide, 15 chremophor, liposomes, or liposome-like products or a silicone fluid, among others.

20

In summary, a great deal of effort has been expended in order to prepare a pharmaceutical composition containing cyclosporin dissolved in an aqueous medium or cyclosporin prepared as an oily solution. However, successful formulations have yet to be accomplished as evidenced by the lack of commercial products.

25

As hereinabove noted, it has been reported that cyclosporin has demonstrated some solubility in oily preparations containing higher fatty acid glycerides such as olive oil, peanut oil, and/or castor oil. 30 These formulations frequently produce an unpleasant sensation when applied to the eye because of stimulation or the viscousness which is characteristic of these oils.

35

Another drawback of these formulations is that they contain a high concentration of oils, and oils exacerbate the symptoms of certain ocular surface

diseases such as dry eyes, indicated by cyclosporin. Therefore, these oily formulations may not be clinically acceptable. Additionally, these formulations often suffer from physical instability due to cyclosporin's propensity to undergo conformational change and crystallize out. The crystallization problem has been noticed in formulations containing corn oil or medium chain triglycerides. Lastly, these formulations often have a low thermodynamic activity (degree of saturation) of cyclosporin which leads to a poorer drug bioavailability.

It may be possible to minimize the problems related to unpleasant sensation and syndrome exacerbation by reducing the oil content and dispersing the oil phase in water into an emulsion. However, it is not an easy task to formulate an ophthalmic emulsion because one indispensable class of ingredients in an emulsion system is emulsifiers, and the majority of emulsifiers is highly irritating to the eyes.

The present invention is directed to an emulsion system which utilizes higher fatty acid glycerides but in combination with polysorbate 80 which results in an emulsion with a high comfort level and low irritation potential suitable for delivery of medications to sensitive areas such as ocular tissues.

SUMMARY OF THE INVENTION

30

In accordance with the present invention, a non-irritating pharmaceutical composition with high comfort level and low irritation potential suitable for delivery to sensitive areas such as ocular tissues comprises cyclosporin in admixture with an emulsifying amount of a higher fatty acid glycerol and polysorbate 80. More particularly, the composition may comprise

35

cyclosporin A and the higher fatty acid glyceride may comprise castor oil.

5 Preferably, the weight ratio of the castor oil to the polysorbate 80 is between about 0.3 to about 30 and a weight ratio of the cyclosporin to castor oil is below 0.16. More preferably, the weight ratio of castor oil to polysorbate 80 is between 0.5 and 12.5, and the weight ratio of cyclosporin to castor oil is
10 between 0.12 and 0.02.

When cyclosporin is dissolved in the oil phase in accordance with the present invention, the emulsion is found to be physically stable upon long term storage.
15 No crystallization of cyclosporin was noticed after nine months at room temperature. Moreover, the cyclosporin emulsion is formulated in such a way that the drug has reasonably high thermodynamic activity, yet without the crystallization problem.

20

DETAILED DESCRIPTION

As hereinabove noted, cyclosporin is available as a mixture in which the principal ingredient is cyclosporin A with significant, but smaller, quantities of
25 other cyclosporins such as cyclosporin B through I. However, as also hereinabove noted, the present invention may be applied to either a pure cyclosporin or to a mixture of individual cyclosporins.

30

The discovery on which the present invention is founded relates to a combination of a higher fatty acid glyceride and an emulsifier and dispersing agent, polysorbate 80. The selection of these components
35 could not have been anticipated on the basis of conventional thinking.

+

For example, although it is well-known that cyclosporin may be used in combination with castor oil, this combination is irritating to sensitive tissues such as the eye. Thus, conventional teaching
5 in the art is away from a formulation which utilizes a higher fatty acid glyceride, such as castor oil, and cyclosporin.

10 Stated another way, there is no way of deducing that the use of an emulsifier and dispersing agent such as polysorbate 80 will reduce the irritation potential of an emulsion utilizing castor oil. There are no examples of polysorbate in combination with castor oil which, when admixed to cyclosporin, pro-
15 duces an emulsion with a high comfort level and low irritation potential suitable for the delivery of medication to sensitive areas such as ocular tissues.

The present invention achieves a stable solution
20 state of cyclosporin. This stable solution state is another important performance characteristic differentiating the present invention from the conventional oil systems. Cyclosporin is notorious for its tendency to precipitate out in conventional oil systems
25 in which it is fully dissolved initially.

In accordance with the present invention, the emulsions can be further stabilized using a polyelectrolyte, or polyelectrolytes if more than one, from
30 the family of cross-linked polyacrylates, such as carbomers and ~~pemulens~~. *Pemulen®*

CT C1
35 In addition, the tonicity of the emulsions can be further adjusted using glycerine, mannitol, or sorbitol if desired. The pH of the emulsions can be adjusted in a conventional manner using sodium hydroxide to a near physiological pH level and while buffering

C
Sp. 1
C

agents are not required, suitable buffers may include phosphates, citrates, acetates and borates.

5 While the preferable medications in accordance with the present invention include cyclosporin, other chemicals which are poorly soluble in water such as indomethacin and steroids such as androgens, prednisolone, prednisolone acetate, fluorometholone, and dexamethasones, may be emulsified with castor oil and
10 polysorbate 80 resulting in a composition with similar low irritation potential.

The invention is further illustrated by the following examples with all parts and percentages
15 expressed by weight. The cyclosporin used in the examples was supplied by Sandoz.

Example 1

190X

C

	A	B	C	D	E
20 Cyclosporin A	0.40%	0.20%	0.20%	0.10%	0.05%
Castor oil	5.00%	5.00%	2.50%	1.25%	0.625%
Polysorbate 80	1.00%	1.00%	1.00%	1.00%	1.00%
Pemulen ^(B)	0.05%	0.05%	0.05%	0.05%	0.05%
Glycerine	2.20%	2.20%	2.20%	2.20%	2.20%
NaOH	qs	qs	qs	qs	qs
25 Purified water	qs	qs	qs	qs	qs
pH	7.2-7.6	7.2-7.6	7.2-7.6	7.2-7.6	7.2-7.6

Example 2

	A	B	C	D
Castor oil	5.00%	2.50%	1.25%	0.625%
Polysorbate 80	1.00%	1.00%	1.00%	1.00%
Pemulen [®]	0.05%	0.05%	0.05%	0.05%
Glycerine	2.20%	2.20%	2.20%	2.20%
NaOH	qs	qs	qs	qs
Purified water	qs	qs	qs	qs
pH	7.2-7.6	7.2-7.6	7.2-7.6	7.2-7.6

Example 3

	A
Castor oil	2.50%
Polysorbate 80	0.75%
Carbomer 1382	0.05%
Glycerine	2.20%
NaOH	qs
Purified water	qs
pH	7.2-7.6

Example 4

	A
Castor oil	5.00%
Polysorbate 80	0.75%
Carbomer 981	0.05%
Glycerine	2.20%
NaOH	qs
Purified water	qs
pH	7.2-7.6

The formulations set forth in Examples 1-4 were made for treatment of keratoconjunctivitis sicca (dry eye) syndrome with Examples 2, 3 and 4 without the active ingredient cyclosporin utilized to determine the toxicity of the emulsified components.

5 The formulations in Examples 1-4 were applied to
rabbit eyes eight times a day for seven days and were
found to cause only slight to mild discomfort and
slight hyperemia in the rabbit eyes. Slit lamp exam-
ination revealed no changes in the surface tissue. In
addition, the cyclosporin containing castor oil emul-
sion, as hereinabove set forth in Examples 1A-1D, was
also tested for ocular bioavailability in rabbits; and
the therapeutic level of cyclosporin was found in the
10 tissues of interest after dosage. This substantiates
that cyclosporin in an ophthalmic delivery system is
useful for treating dry eye as set forth in U.S.
Patent No. 4,839,342.

15 In addition, no difference in toxicity was found
between formulations with cyclosporin (Examples 1A-1D)
and formulations without cyclosporin (Examples 2-4).

20 The formulations set forth in Examples 1-4 were
found to be physically stable upon long term storage.
With regard to formulations 1A-1D, no crystallization
of cyclosporin was noticed after nine months at room
temperature.

25 Further, other higher fatty acid glycerides such
as olive oil, peanut oil and the like may also be
utilized with the polysorbate 80 with similar results
regarding biotoxicity.

30 Although there has been hereinabove described a
particular pharmaceutical composition in the form of
a nonirritating emulsion for the purpose of illustrat-
ing the manner in which the invention may be used to
advantage, it should be appreciated that the invention
35 is not limited thereto. Accordingly, any and all mod-
ifications, variations, or equivalent arrangements,
which may occur to those skilled in the art, should be

considered to be within the scope of the present invention as defined in the appended claims.